Aniracetam: The Definitive Guide

What is aniracetam?

Aniracetam is a synthetic pyrrolidinone in the racetam family. It has been studied as a medicine for cognitive disorders and as a positive modulator of AMPA-type glutamate signaling. It is not a vitamin, food component or essential nutrient. [4], [5]

The clinical record is narrower than its online reputation. A six-month placebo-controlled dementia trial reported psychobehavioral improvement, and a small healthy-volunteer experiment partly reversed cognitive impairment deliberately caused by scopolamine. Neither study tested ordinary focus, creativity or learning in unimpaired people going about daily life. [1], [2]

Online availability creates another problem: the label may not identify the product accurately, and authorization differs by country. Treat the exact product, source and jurisdiction as part of the evidence question.

Typical Aniracetam Research Protocols

The same number can mean different things in different designs. The Wesnes 1,500 mg exposure was a single dose after scopolamine had impaired cognition. The Lee review reports 1,500 mg per day for historical dementia trials, but that daily total cannot be divided into assumed administrations without the primary methods. [2], [4]

Product identity

Record manufacturer, dosage form, lot, declared strength, purchase or dispensing source and any independent analytical result.

Administration

Keep amount each time, daily total, food context and co-medications separate; do not reconstruct a missing split.

Clinical context

Record diagnosis or study model, baseline cognition, sleep and mood, and the exact endpoint selected before exposure.

What is aniracetam commonly used for?

Dementia and cognitive impairment

Senin and colleagues randomized 109 older adults with probable mild-to-moderate Alzheimer-type dementia to aniracetam or placebo for six months. The abstract reports statistically significant psychobehavioral differences at the end and excellent tolerability. It does not give the effect size, attrition, named primary endpoint or enough method detail for a contemporary risk-of-bias judgment. [1]

Koliaki and colleagues later evaluated 276 people in an open comparison of no treatment, aniracetam, cholinesterase inhibitors or both. Seven people who switched treatment were excluded, leaving 269 analyzed. The rater was blinded, but assignment was not computer-randomized; the aniracetam group began with better cognition and function and included more mild cognitive impairment. Maintained outcomes therefore remain vulnerable to baseline imbalance, treatment selection and post-assignment exclusion. [3]

Healthy cognition and scopolamine challenge

Wesnes tested 26 healthy volunteers across seven visits after 0.7 mg subcutaneous scopolamine. A single 1,500 mg oral aniracetam exposure improved some induced memory and information-processing decrements. This shows activity in a cholinergic-blockade model. It does not show reliable improvement above a normal baseline or support chronic use. [2]

Amyloid prevention and mechanism

The 2024 Love paper proposes that AMPA, BDNF and alpha-secretase pathways could reduce amyloid-beta production. The paper also states that no direct human or animal study had tested aniracetam on amyloid production or accumulation. The proposal and its suggested future protocol are research questions, not prevention evidence. [6]

How might it work?

Aniracetam is described as a positive allosteric modulator of AMPA signaling and is rapidly converted into metabolites, including N-anisoyl-GABA. Reviews discuss downstream cholinergic, glutamatergic, dopamine and serotonin effects. These mechanisms help explain why it was investigated; they do not establish a clinical benefit, a “creativity” effect or an anti-anxiety treatment in humans. [5]

How do forms and labels differ?

Aniracetam is one synthetic molecule, but a finished product can be a dispensed medicine, imported tablet, capsule or bulk powder. Those formats differ in authorization, manufacturing controls and traceability. Powder bitterness, capsule size or vendor certificates do not establish identity.

Laboratory analyses of products sold for cognitive enhancement have found inaccurate quantities and unlisted drug ingredients. In January 2026, FDA posted a recall of a product with undeclared aniracetam, tianeptine and 1,4-DMAA. These findings do not quantify every product on the market, but they make source verification a core safety issue. [7]–[9]

How should aniracetam be stored?

Follow the authorized pharmacy label where one exists. Keep the product in its original labeled container, dry, away from heat and inaccessible to children. Do not keep unidentified bulk powder beside food or routine supplements. Storage cannot correct contamination, substitution or an inaccurate label.

What does the human evidence show?

What are the risks and interactions?

Older reports describe anxiety, uneasiness, insomnia, headache, vertigo, nausea, diarrhea, abdominal discomfort, urinary urgency and rash. Small studies and short abstracts cannot define uncommon harms or long-term risk. A gray-market product adds the possibility of wrong amount, substitution or undeclared co-ingredients. [1], [4], [7]

Aniracetam has central nervous system activity. Sedatives, stimulants, antidepressants, antipsychotics, seizure medicines and cholinesterase inhibitors can complicate symptoms or attribution. Claims that everyone “needs choline” are not established by controlled evidence, and adding another active product adds another source of effects.

Avoid self-treatment during pregnancy, breastfeeding or childhood, and do not use an online racetam to manage dementia, stroke symptoms, anxiety or depression. Seek urgent care for seizure, severe agitation or confusion, fainting, chest pain, allergic symptoms, or a sudden neurologic change.

What is the legal and regulatory status?

In the United States, FDA has cited aniracetam in unauthorized drug-claim enforcement and a 2026 recall of a product containing undeclared aniracetam. That record does not make it an accepted dietary ingredient. In other countries, historical medicine use does not establish that a current vendor or imported product is authorized. [8], [9]

In Canada, verify the finished product in the Drug Product Database for a DIN or the Licensed Natural Health Products Database for an NPN. A marketplace listing, customs arrival or vendor assay is not proof of authorization. [10]

When should use stop?

Stop an unverified product and seek clinical advice for new neurologic symptoms, marked insomnia, agitation, mood change, rash or persistent GI effects. Do not abruptly change a prescribed cognitive or neurologic medicine because of this guide; involve the prescriber.

What should be monitored?

Define the target before exposure: one validated cognitive measure in clinical care, or one specific symptom rather than a broad impression. Record sleep, mood, headache, GI effects and every co-medication. Review whether the product and outcome are still identifiable after any formulation or schedule change.

For dementia or cognitive impairment, clinician assessment, functional change, medication review and evaluation for reversible causes matter more than a self-rated “clarity” score. A consumer log does not replace diagnosis.

What does community experience add?

Public reports may flag bitter powder, headaches, sleep disruption, timing and sourcing problems. They cannot establish identity, a universal choline requirement, an anti-anxiety effect or reliable cognitive benefit. No systematic current community sample was assembled, so this guide reports no consensus dose, meal rule, cycle or withdrawal rate.

How does aniracetam compare with related options?

Common questions

Is aniracetam a supplement?

It is a synthetic drug-like compound, not an essential dietary nutrient. A supplement-style label does not settle its legal category or product identity.

Does aniracetam improve focus or creativity in healthy people?

No robust controlled evidence establishes that use. The healthy-volunteer study deliberately impaired participants with scopolamine first. [2]

Did a trial use 1,500 mg?

Yes, as one oral administration during a scopolamine-challenge visit. A historical review also reports 1,500 mg/day in dementia studies. Those contexts are not interchangeable. [2], [4]

Does it prevent Alzheimer’s disease?

No direct evidence establishes prevention. The 2024 paper is a mechanistic hypothesis and explicitly says direct amyloid studies were absent. [6]

Should aniracetam be taken with fat?

Lipophilicity is often used to justify this advice, but the checked human protocols did not establish a universal meal or fat requirement. Do not turn a chemical property into an untested instruction.

Does it require a choline supplement?

No controlled evidence establishes a universal requirement. Adding choline can add its own effects and makes attribution harder.

Can an online certificate prove purity?

No. It may add information about one sample, but it does not replace regulator authorization, traceable lot testing or independent verification of the product received.

Is aniracetam approved in Canada?

Verify the exact finished product in Health Canada’s current databases. Do not infer authorization from historical use elsewhere or from an online listing.

Glossary

Plain explanations of aniracetam evidence terms.

Racetam

A family of synthetic pyrrolidone compounds marketed or studied for neurologic and cognitive effects.

AMPA receptor

A glutamate receptor involved in fast excitatory signaling; receptor modulation is a mechanism, not proof of benefit.

Scopolamine challenge

A laboratory model that temporarily impairs cognition through anticholinergic activity.

Open study

A study where treatment is known; expectation and selection can influence findings.

Positive allosteric modulator

A compound that changes receptor response by binding away from the main signaling site.

DIN

Canadian Drug Identification Number for an authorized drug product.

NPN

Canadian Natural Product Number for a licensed natural health product.

How this guide was researched

Nine PubMed identities were checked through live NCBI EFetch, including title, authors, journal, volume, issue, pagination, DOI and descendant publication-status records. Primary abstracts supplied the exact populations and administration details they reported. The full 2024 hypothesis paper established that the amyloid claim remains untested. FDA records and laboratory studies supplied current product-quality context.

Explore the sources

Related guides

• Piracetam
• Oxiracetam
• Phenylpiracetam
• Noopept
• Nootropic compounds

Editorial note

This guide keeps old dementia trials, an induced-impairment experiment, mechanistic hypotheses and gray-market product evidence separate. It does not turn any study exposure into a consumer regimen.